There are multiple ways to target Tregs for cancer immunotherapies, including utilizing Abs against Treg activation molecules, such as CD25, CTLA4, and OX40, and strategies to block the chemokine receptor CCR4 (37, 51–57). The gene discussed is CTLA4; the disease is cancer.